Table 1 Demographic data of the study population and the results of lung function tests.
From: Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
All n (%) | R cases (n = 574) | NR cases (n = 431) | S cases (n = 334) | |
|---|---|---|---|---|
Men (%) | 48 | 52 | 44 | 49 |
Smoking status | ||||
Smokers, no. (%) | 737 (55) | 423 (74) | 177 (41) | 137 (41) |
Never-smokers no. (%) | 602 (45) | 151 (26) | 254 (59) | 197 (59) |
Respiratory symptoms at inclusion, no. (%) | 839 (63) | 574 | 166 (38) | 99 (30) |
Deaths, no. (%) | 315 (24) | 212 (37) | 79 (18) | 24 (7) |
Lung transplant (no.) | 56 | 51 | 3 | 2 |
Liver transplant (no.) | 2 | - | 2 | - |
Mean (range) age at diagnosis (years) | 41 (0-88) | 51 (0.1-88) | 40 (0.01-84) | 24 (0-77) |
Mean (range) age at inclusion (years) | 47 (18-89) | 54 (18-89) | 45 (18-87) | 35 (18-78) |
Mean (range) follow-up time (years) | 9 (0.02-17) | 8 (0.02-17) | 10 (0.02-17) | 11 (0.07-17) |
Mean age (range) at death | 67 (20-95) | 67 (30-95) | 69 (20-90) | 61 (37-85) |
Mean (SD) FEV1 (% predicted) | 72 (33) | 50 (29)* | 88 (25) | 89 (23) |
Mean (SD) FVC (% predicted) | 84 (23) | 75 (25)* | 89 (18) | 93 (16) |
Mean (SD) FEV1/FVC ratio (%) | 63 (23) | 48 (22)* | 75 (17) | 76 (15) |